BCL2L1 and liver cancer: It is interesting to note that, unlike ABT-737, ABT-199 that primarily targets BCL-2 was unable to induce efficient cell death in combination with sorafenib or regorafenib in liver cancer cells [24, 45], indicating that targeting of BCL-XL, e.g., by ABT-737, might be more effective in HCC.